

Claims:

1. The use of an early stage mevalonate pathway blocker in the manufacture of a medicament for the prevention or amelioration of an acute phase response in a patient being treated or about to be, or intended to be, treated with a bisphosphonate.
2. Use according to claim 1, wherein the patient is undergoing bisphosphonate therapy or prophylaxis.
3. Use according to claim 1, wherein the patient is about to undergo bisphosphonate therapy or prophylaxis.
4. Use according to any preceding claim, wherein the bisphosphonate is associated with, or is suspected of being associated with, an increased risk of acute phase response.
5. Use according to any preceding claim, wherein the patient is human.
6. Use according to any of claims 1 to 4, wherein the patient is non-human.
7. Use according to claim 6, wherein the patient is a horse or a cat.
8. Use according to any preceding claim, wherein the medicament is formulated for oral administration.
9. Use according to any preceding claim, wherein the bisphosphonate is a nitrogen containing bisphosphonate.
10. Use according to claim 9, wherein the bisphosphonate is pamidronate, dimethyl pamidronate, alendronate, ibandronate, risedronate, zoledronate, or combination thereof.
11. Use according to any preceding claim, wherein the early stage mevalonate pathway blocker is an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase.
12. Use according to claim 11, wherein the early stage mevalonate pathway blocker is a statin.
13. Use according to claim 12, wherein the statin is simvastatin, lovastatin, atorvastatin, fluvastatin, mevinolin, or a combination thereof.
14. Use according to any preceding claim, wherein the indication for which the patient is receiving, or is about to receive, the bisphosphonate is selected from the group

consisting of: osteoporosis, Paget's disease, skeletal metastases, fibrous dysplasia, Charcot's arthropathy, sympathetic dystrophy, pachydermic periostosis, aseptic osteomyelitis, multiple myeloma, hypercalcaemia, atherosclerosis and diabetes.

15. A kit comprising:

a first medicament comprising an early-stage mevalonate pathway blocker, and
a second medicament comprising bisphosphonate,

together with an indication that the first medicament should be taken no later than the second medicament.

16. A kit according to claim 15, wherein the indication is that first medicament should be taken from several hours before the bisphosphonate to several days before the second medicament.

17. A kit according to claim 16, wherein there is an indication to the first medicament before the second medicament, and wherein extra of the first medicament comprising early-stage mevalonate pathway inhibitor is provided.

18. A use or kit, according to any preceding claim, wherein the medicaments are provided in a form suitable for oral administration.

19. A method for preventing or ameliorating an acute phase response in a patient receiving, or about to receive, bisphosphonate treatment, comprising administering an effective amount of an early-stage mevalonate pathway blocker thereto.